Product Image

Contributor Information

  • Name Anne-Marie Mes-Masson and Diane Provencher
  • Institute Centre Hospitalier de L’université de Montréal
  • Primary citation Sauriol A et al. 2020. Cancers. 12(8):2222. PMID: 32784519

Tool Details

  • Tool name: TOV-2929D cell line
  • Alternate names: TOV-2929D
  • Tool type: Cell Lines
  • Organism: Human
  • Donor: Grade 3 – Stage IIIC; Mutations: TP53 Exon 7; Pre-treatment for ovarian cancer/ colon cancer 5 years before
  • Tissue: Derived from solid tumor of patient diagnosed with high-grade serous ovarian cancer at specific time points at diagnosis and relapse
  • Gender: Female
  • Cancer type: Gynaecologic cancer
  • Morphology: Characteristic flattened cobblestone-like appearance. Formed compact flat discs rather than spherical spheroids.
  • Growth properties: Adherent
  • CRISPR: No
  • Receptors of note: No
  • Description: Epithelial ovarian cancer cell lines spontaneously derived from solid tumor of patient diagnosed with high-grade serous ovarian cancer. Sample taken from solid tissue of the ovary, specifically derived from samples of the right ovary
  • Research area: Cancer
  • Production details: Established using the Scrape method where tumor tissue was scraped into a 100mm plate with complete OSE medium and maintained for 40 days with medium replaced weekly.
  • Additional notes: Patient 2929 was age 77 at time of diagnosis with prior history of colorectal cancer. Patient was chemonaive at the time of sampling and sampling took place in 2006.

  • For Research Use Only

Target Details

Application Details

Handling

  • Growth medium: OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin
  • Temperature: 37C
  • Atmosphere: Low oxygen conditions of 7% O2 and 5% CO2
  • Cultured in antibiotics?: Amphotericin B and Gentamicin

Documentation

Related Tools

Product Image

MuCap4 [P379.1] CRPC Cell line

#161842
Product Image

RLUN016-2 Lung cancer organoid

#160945
Product Image

R-3327 G cell line

#156408

References

  • •  Gaia-Oltean et al. 2021. Exp Ther Med. 21(3):243. PMID: 33603851 Canals Hernaez et al. 2020. J Immunother Cancer. 8(2):e001128. PMID: 33243933 Borzdzi?owska et al. 2022. Biomedicines. 11
  • •  10(5):1116. PMID: 35625852 Meng et al. 2023. J Anim Sci. 3
  • •  101:skad215. PMID: 37351870 Koni et al. 2020. Int J Mol Sci. 18
  • •  21(20):7697. PMID: 33080952